BACKGROUND: We investigated the efficacy and toxicity of a regimen consisting of paclitaxel and gemcitabine plus nedaplatin, a derivative of cisplatin (TGN) in patients with heavily pretreated cisplatin-refractory germ cell tumors (GCTs). METHODS: Fifteen patients with advanced GCTs were treated with the TGN regimen. The combination chemotherapy consisted of paclitaxel (210 mg/m(2)) on day 1 and gemcitabine (1000 mg/m(2)) on days 1 and 8 in combination with nedaplatin (100 mg/m(2)) on day 2 every 3 weeks. RESULTS: Patients enrolled in this study had been heavily pretreated with a median of 12 platinum-containing cycles (range, 7 to 26 cycles). Most of the regimens had included paclitaxel and ifosfamide plus cisplatin or nedaplatin (TIP/TIN) chemotherapy. The median follow-up period of the present study was 15 months. Patients received 2-11 cycles of the TGN combination chemotherapy. Six patients received the treatment combined with other therapeutic modalities; 2 patients received radiation therapy for retroperitoneal lymph node metastasis, 1 patient had cyber-knife radiosurgery for brain metastasis and 3 patients had radiofrequency ablation for liver and lung metastasis. Seven (46.7%) of the 15 patients achieved an objective response; 6 had marker-negative partial responses (PRs) and 1 had a marker-positive PR. Two (13%) of the 7 patients with PRs achieved a disease-free status after chemotherapy combined with RT and followed by surgical resection. However, 10 patients died of the disease and 3 patients are still alive with the disease. CONCLUSION: The TGN regimen alone had limited efficacy in this patient population, with severe but manageable toxicities. However, TGN chemotherapy may offer a chance of cure for some heavily pretreated cisplatin-refractory (TIP/TIN-refractory) patients as part of multidisciplinary therapy.
BACKGROUND: We investigated the efficacy and toxicity of a regimen consisting of paclitaxel and gemcitabine plus nedaplatin, a derivative of cisplatin (TGN) in patients with heavily pretreated cisplatin-refractory germ cell tumors (GCTs). METHODS: Fifteen patients with advanced GCTs were treated with the TGN regimen. The combination chemotherapy consisted of paclitaxel (210 mg/m(2)) on day 1 and gemcitabine (1000 mg/m(2)) on days 1 and 8 in combination with nedaplatin (100 mg/m(2)) on day 2 every 3 weeks. RESULTS:Patients enrolled in this study had been heavily pretreated with a median of 12 platinum-containing cycles (range, 7 to 26 cycles). Most of the regimens had included paclitaxel and ifosfamide plus cisplatin or nedaplatin (TIP/TIN) chemotherapy. The median follow-up period of the present study was 15 months. Patients received 2-11 cycles of the TGN combination chemotherapy. Six patients received the treatment combined with other therapeutic modalities; 2 patients received radiation therapy for retroperitoneal lymph node metastasis, 1 patient had cyber-knife radiosurgery for brain metastasis and 3 patients had radiofrequency ablation for liver and lung metastasis. Seven (46.7%) of the 15 patients achieved an objective response; 6 had marker-negative partial responses (PRs) and 1 had a marker-positive PR. Two (13%) of the 7 patients with PRs achieved a disease-free status after chemotherapy combined with RT and followed by surgical resection. However, 10 patients died of the disease and 3 patients are still alive with the disease. CONCLUSION: The TGN regimen alone had limited efficacy in this patient population, with severe but manageable toxicities. However, TGN chemotherapy may offer a chance of cure for some heavily pretreated cisplatin-refractory (TIP/TIN-refractory) patients as part of multidisciplinary therapy.
Authors: J-L Pico; G Rosti; A Kramar; H Wandt; V Koza; R Salvioni; C Theodore; G Lelli; W Siegert; A Horwich; M Marangolo; W Linkesch; G Pizzocaro; H-J Schmoll; J Bouzy; J-P Droz; P Biron Journal: Ann Oncol Date: 2005-05-31 Impact factor: 32.976
Authors: C Bokemeyer; A Gerl; P Schöffski; A Harstrick; N Niederle; J Beyer; J Casper; H J Schmoll; L Kanz Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: C Kollmannsberger; O Rick; H-G Derigs; N Schleucher; P Schöffski; J Beyer; R Schoch; H G Sayer; A Gerl; M Kuczyk; C Spott; L Kanz; C Bokemeyer Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: C Bokemeyer; J Beyer; B Metzner; U Ruther; A Harstrick; L Weissbach; U Kohrmann; W Verbeek; H J Schmoll Journal: Ann Oncol Date: 1996-01 Impact factor: 32.976
Authors: H Akaza; M Togashi; Y Nishio; T Miki; T Kotake; Y Matsumura; O Yoshida; Y Aso Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333
Authors: R J Motzer; D F Bajorin; L H Schwartz; H S Hutter; G J Bosl; H I Scher; P Lyn; P Fischer Journal: J Clin Oncol Date: 1994-11 Impact factor: 44.544
Authors: C Kollmannsberger; O Rick; H Klaproth; T Kubin; H G Sayer; M Hentrich; M Welslau; F Mayer; M Kuczyk; C Spott; L Kanz; C Bokemeyer Journal: Br J Cancer Date: 2002-09-23 Impact factor: 7.640